UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

The New England journal of medicine, 2021-04, Vol.384 (14), p.1289-1300

2021

Volltextzugriff (PDF)

Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex

Pediatric neurology, 2020-04, Vol.105, p.59-61

2020

Volltextzugriff (PDF)

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

PloS one, 2016-06, Vol.11 (6), p.e0158476-e0158476

2016

Volltextzugriff (PDF)

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

European urology, 2017-12, Vol.72 (6), p.962-971

2017

Volltextzugriff (PDF)

The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy

Neuropharmacology, 2018-09, Vol.140, p.107-120

2018

Volltextzugriff (PDF)

Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation

Journal of the American Society of Nephrology, 2018-07, Vol.29 (7), p.1979-1991

2018

Volltextzugriff (PDF)

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma

European urology, 2018-04, Vol.73 (4), p.628-634

2018

Volltextzugriff (PDF)

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

European urology, 2016-05, Vol.69 (5), p.866-874

2016

Volltextzugriff (PDF)

Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway

Medicine (Baltimore), 2024-08, Vol.103 (32), p.e39244

2024

Volltextzugriff (PDF)

Two‐year outcomes in de novo renal transplant recipients receiving everolimus‐facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study

American journal of transplantation, 2019-11, Vol.19 (11), p.3018-3034

2019

Volltextzugriff (PDF)

Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer

Investigational new drugs, 2021-12, Vol.39 (6), p.1707-1715

2021

Volltextzugriff (PDF)

Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure‐Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibitor)

Journal of clinical pharmacology, 2024-09, Vol.64 (9), p.1101-1111

2024

Volltextzugriff (PDF)

Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship

Pharmacological research, 2017-07, Vol.121, p.138-144

2017

Volltextzugriff (PDF)

Safety of mTOR inhibitors in adult solid organ transplantation

Expert opinion on drug safety, 2016-03, Vol.15 (3), p.303-319

2016

Volltextzugriff (PDF)

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis

Annals of neurology, 2015-12, Vol.78 (6), p.929-938

2015

Volltextzugriff (PDF)

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

PloS one, 2017-08, Vol.12 (8), p.e0180939-e0180939

2017

Volltextzugriff (PDF)

Population pharmacokinetics of everolimus in renal transplant recipients receiving long-term multiple immunosuppressive therapy

Drug metabolism and pharmacokinetics, 2024-06, Vol.56, p.101009, Article 101009

2024

Volltextzugriff (PDF)

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Breast cancer research : BCR, 2021-01, Vol.23 (1), p.14-10, Article 14

2021

Volltextzugriff (PDF)

Everolimus

Small Molecules in Oncology, 2018, Vol.211, p.101-123

2018

Volltextzugriff (PDF)

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

The Lancet (British edition), 2016-10, Vol.388 (10056), p.2153-2163

2016

Volltextzugriff (PDF)

Cannabidiol Interacts Significantly with Everolimus-Report of a Patient with Tuberous Sclerosis Complex

Neuropediatrics, 2019-12, Vol.50 (6), p.400-403

2019

Volltextzugriff (PDF)

Therapeutic Drug Monitoring of Everolimus: A Consensus Report

Therapeutic drug monitoring, 2016-04, Vol.38 (2), p.143-169

2016

Volltextzugriff (PDF)

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

Annals of oncology, 2017-07, Vol.28 (7), p.1569-1575

2017

Volltextzugriff (PDF)

Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma

Gene, 2022-01, Vol.809, p.145992-145992, Article 145992

2022

Volltextzugriff (PDF)

Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease

The New England journal of medicine, 2024-01, Vol.390 (1), p.9-19

2024

Volltextzugriff (PDF)

1 – 25 von 7.161

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(6.419)
Mit Volltextzugriff
(5.734)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

12 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(6.019)
Life Sciences & Biomedicine
(5.859)
Everolimus
(5.427)
Humans
(5.128)
Female
(2.811)
Sirolimus - Analogs & Derivatives
(2.727)
Male
(2.574)
Middle Aged
(2.104)
Oncology
(1.764)
Treatment Outcome
(1.740)
Aged
(1.728)
Cardiovascular System & Cardiology
(1.462)
Cardiac & Cardiovascular Systems
(1.415)
Sirolimus - Therapeutic Use
(1.275)
Drug-Eluting Stents
(1.168)
Adult
(1.130)
Sirolimus - Administration & Dosage
(1.092)
Immunosuppressive Agents - Therapeutic Use
(923)
Everolimus - Therapeutic Use
(896)
Biological And Medical Sciences
(893)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(5.490)
EZB Electronic Journals Library
(3.530)
IngentaConnect
(3.264)
Ovid SocietyJournals and Single Titles
(2.766)
Access via ScienceDirect (Elsevier)
(1.524)
IngentaConnect Journals
(1.445)
Access via Wiley Online Library
(908)
SpringerLink
(829)
Single Journals
(817)
Wiley Online Library Full Collection 2018
(738)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(638)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(481)
Access via Taylor & Francis
(438)
Taylor & Francis
(341)
Nexis Uni
(338)
Taylor & Francis Online
(230)
Access via Oxford University Press
(174)
Oxford Journals 2020 Medicine
(153)
Nature Journals
(125)
SAGE Publications
(114)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(14)
... seit 90 Tagen
(30)

Menü

Weitere Dienste

Einstellungen

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy

Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

Pharmacokinetic variability of everolimus and impact of concomitant antiseizure medications in patients with tuberous sclerosis complex: A retrospective study of therapeutic drug monitoring data in Denmark and Norway

Two‐year outcomes in de novo renal transplant recipients receiving everolimus‐facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study

Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer

Quantitative Assessment of Drug Efficacy and Emergence of Resistance in Patients with Metastatic Renal Cell Carcinoma Using a Longitudinal Exposure‐Tumor Growth Inhibition Model: Apitolisib (Dual PI3K/mTORC1/2 Inhibitor) Versus Everolimus (mTORC1 Inhibitor)

Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship

Safety of mTOR inhibitors in adult solid organ transplantation

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

Population pharmacokinetics of everolimus in renal transplant recipients receiving long-term multiple immunosuppressive therapy

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

Everolimus

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

Cannabidiol Interacts Significantly with Everolimus-Report of a Patient with Tuberous Sclerosis Complex

Therapeutic Drug Monitoring of Everolimus: A Consensus Report

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

Everolimus accelerates Erastin and RSL3-induced ferroptosis in renal cell carcinoma

Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease

Suchergebnisse filtern